Compare MITT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITT | TLSI |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.6M | 151.2M |
| IPO Year | 2011 | 2020 |
| Metric | MITT | TLSI |
|---|---|---|
| Price | $3.92 | $2.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $8.33 | $7.80 |
| AVG Volume (30 Days) | ★ 486.6K | 301.2K |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | ★ 24.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | N/A | $3.46 |
| Revenue Next Year | $10.23 | $19.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $3.77 | $2.17 |
| 52 Week High | $9.27 | $7.95 |
| Indicator | MITT | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 20.56 | 32.26 |
| Support Level | N/A | $2.20 |
| Resistance Level | $8.15 | $4.59 |
| Average True Range (ATR) | 0.28 | 0.37 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 5.12 | 9.26 |
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.